2.04 0.01 (0.49%) | 04-17 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.31 | 1-year : | 4.01 |
Resists | First : | 2.84 | Second : | 3.44 |
Pivot price | 2.81 | |||
Supports | First : | 1.87 | Second : | 1.55 |
MAs | MA(5) : | 2.42 | MA(20) : | 2.86 |
MA(100) : | 3.18 | MA(250) : | 2.64 | |
MACD | MACD : | -0.3 | Signal : | -0.2 |
%K %D | K(14,3) : | 7.9 | D(3) : | 9.4 |
RSI | RSI(14): 29.3 | |||
52-week | High : | 4.26 | Low : | 1.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PSTX ] has closed below the lower bollinger band by 4.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 63.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 2.08 - 2.09 | 2.09 - 2.11 |
Low: | 1.88 - 1.9 | 1.9 - 1.91 |
Close: | 2.02 - 2.04 | 2.04 - 2.06 |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Wed, 17 Apr 2024
2024-04-17 | NDAQ:PSTX | Press Release | Poseida Therapeutics Inc - Stockhouse Publishing
Tue, 09 Apr 2024
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27% - Simply Wall St
Mon, 01 Apr 2024
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Mon, 25 Mar 2024
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer - BioSpace
Mon, 11 Mar 2024
Is it Time to Dump Poseida Therapeutics Inc (PSTX) Stock After it Is Lower By 1.36% in a Week? - InvestorsObserver
Sun, 10 Mar 2024
US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 96 (M) |
Shares Float | 55 (M) |
Held by Insiders | 34.5 (%) |
Held by Institutions | 47.5 (%) |
Shares Short | 4,120 (K) |
Shares Short P.Month | 3,450 (K) |
EPS | -1.38 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.08 |
Profit Margin | -190.8 % |
Operating Margin | -103.7 % |
Return on Assets (ttm) | -25.9 % |
Return on Equity (ttm) | -84.8 % |
Qtrly Rev. Growth | 148.6 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.67 |
EBITDA (p.s.) | -1.29 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -92 (M) |
Levered Free Cash Flow | -41 (M) |
PE Ratio | -1.49 |
PEG Ratio | -0.7 |
Price to Book value | 1.88 |
Price to Sales | 3.04 |
Price to Cash Flow | -2.14 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |